Navigation Links
Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Date:2/24/2010

uch risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

    For further information please contact:

    Investor Relations:
    Clea Rosenfeld (Rest of the World),
    +44-1256-894-160;

    Eric Rojas (North America),
    +1-617-551-9715.

    Media:
    Jessica Mann (Rest of the World),
    +44-1256-894-280.

    Jessica Cotrone (North America, HGT),
    +1-781-482-9538.


SOURCE Shire Pharmaceutical

Back to top
'/>"/>
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
2. New Shire Board Member
3. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
4. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
5. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
6. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
7. Shire Initiates Two Adult ADHD Outreach Programs
8. Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
9. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
10. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
11. Shire begins the year with a strong performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/31/2014)... 2014 2014 Market Research ... professional and in-depth research report on the ... information, including Polyacrylamide definition, classification, application, and ... overview. This research covers the international market ... global industry analysis covering macroeconomic environment & ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 The ... a professional and in-depth study on the current ... Global and China. , The report provides a ... and industry chain structure. Global market analysis and ... focus on history, developments, trends and competitive landscape ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2
... SyntheMed, Inc. ("the Company") (OTCBB: SYMD; Pink Sheets: ... on the treatment of diseases characterized by organ-specific cell damage, ... 2011.  The Company changed its name to "Pathfinder Cell Therapy, ... OTC Bulletin Board, changing to a new trading symbol shortly. ...
... 2011 Omeros Corporation (NASDAQ: OMER ... developing and commercializing products targeting inflammation, coagulopathies and ... that Gregory A. Demopulos, M.D., chairman and chief ... Rodman and Renshaw 13th Annual Healthcare Conference taking ...
... The inaugural  European Neurotech Investing ... It features keynotes on the state of the European neurotech ... presentations on next generation treatments emerging in the EU for ... Alzheimer , s, addiction, depression, schizophrenia, Parkinson ...
Cached Biology Technology:Pathfinder, LLC and SyntheMed, Inc. Complete Merger 2Pathfinder, LLC and SyntheMed, Inc. Complete Merger 3High-Level Neurotech Summit Brings Companies, Researchers and Investors Together in Helsinki 2High-Level Neurotech Summit Brings Companies, Researchers and Investors Together in Helsinki 3
(Date:8/29/2014)... the type and number of connections in transcription factor ... robustness in a study published in PLOS Computational ... the assortativity signature contributes to a network,s resilience against ... the out-out assortativity of TFN models has a greater ... three types of assortativity," said Dov A. Pechenick, PhD, ...
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
(Date:8/29/2014)... rise of the Tibetan plateau -- the largest topographic ... for both its profound effect on climate and its ... GSA Bulletin , Katharine Huntington and colleagues employ ... using modern and fossil snail shells to investigate the ... , Views range widely on the timing of ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7
... Massey Cancer Center studying the interaction between the ... gamma as one of the signaling proteins involved ... researchers develop tailored vaccines and other immunotherapeutic strategies ... the manipulation of the immune system ?by introducing ...
... M.D. and Ami Klin are part of a global research ... region of a chromosome that may lead to autism in ... Genetics and also will be published in the journal’s March ... scan. Over 120 scientists from over 50 institutions who formed ...
... cause of high blood pressure lies within the brain, and ... by scientists at the University of Bristol, UK, and is ... Waki, working in a research group led by Professor Julian ... (junctional adhesion molecule-1), which is located in the walls of ...
Cached Biology News:Mechanisms involved with tumor relapse identified 2Autism gene identified by researchers at Yale working with a global research consortium 2Blame the brain for high blood pressure 2
... IMPACT (Intein Mediated Purification with an ... activity of engineered protein splicing elements (termed ... single affinity column (1-4) (Figures 1 and ... protein fusion systems by its ability to ...
... all the reagents required for a fast ... activity in cell and tissue extracts and ... has been tested on samples prepared from ... spleen, and heart muscle from several species, ...
... CHEMICON's Skeletal Myogenesis Kit provides ... C2C12 myoblasts into mature skeletal myotubes. ... kit is a valuable tool in ... and in developing strategies for muscle ...
... Detection Assay is an anchorage-independent growth assay ... most stringent assay for detecting malignant transformation ... (pre-treated with carcinogens or carcinogen inhibitors) are ... medium for 21-28 days. Following this ...
Biology Products: